top of page
  • EVI

TRANSVAC2 and the vaccine R&D infrastructure in the European Union

07 June 2023

A Collaborative Vision: A new article highlighting the efforts to establish a robust vaccine research and development (R&D) infrastructure in the European Union (EU) has been recently published, emphasizing the importance of integration and collaboration in advancing vaccine R&D.

The EVI-led TRANSVAC2 project has played a significant role in the EU’s creation of a supportive European framework which fosters scientific innovation and supports the accelerated development of life-saving vaccines.

By prioritising vaccine infrastructure, we can enhance research capabilities, streamline processes, and improve the efficiency of vaccine development. This investment strengthens our preparedness for future health crises and benefits public health worldwide.

The European Union's commitment to establishing a robust vaccine R&D infrastructure is a testament to its unwavering dedication to public health. By fostering collaboration, investing in cutting-edge facilities, streamlining regulatory processes, and nurturing public-private partnerships, the EU is paving the way for rapid vaccine development and deployment.

To gain deeper insights into this dynamic field and stay informed about the latest advancements, we encourage you to explore the comprehensive article on the history and outlook of vaccine infrastructures in the European Union: Vaccine Research and Development Infrastructure in the European Union: Establishing Support Through Integration.

Together, we can combat global health challenges and build a safer, healthier future for all. Visit TRANSVAC Services page to learn more about our network’s areas of expertise and current opportunities for vaccine developers.


Photo credit: BioProcess International

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.


bottom of page